• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma.

作者信息

Lindholm Kaleigh E, Forsberg Peter A, Ewalt Mark D

机构信息

Department of Pathology University of Colorado Anschutz Medical Campus Aurora Colorado USA.

Department of Medicine Division of Hematology, University of Colorado Anschutz Medical Campus Aurora Colorado USA.

出版信息

EJHaem. 2021 Jun 20;2(3):565-568. doi: 10.1002/jha2.253. eCollection 2021 Aug.

DOI:10.1002/jha2.253
PMID:35844727
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9176001/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1113/9176001/e8fb64d6761e/JHA2-2-565-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1113/9176001/3a0a9ab82fd0/JHA2-2-565-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1113/9176001/e8fb64d6761e/JHA2-2-565-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1113/9176001/3a0a9ab82fd0/JHA2-2-565-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1113/9176001/e8fb64d6761e/JHA2-2-565-g001.jpg

相似文献

1
Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma.伊布替尼治疗皮肤转化型淋巴浆细胞淋巴瘤的疗效
EJHaem. 2021 Jun 20;2(3):565-568. doi: 10.1002/jha2.253. eCollection 2021 Aug.
2
Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment.淋巴浆细胞淋巴瘤及依鲁替尼治疗期间的慢性戊型肝炎病毒感染
Pathogens. 2019 Aug 22;8(3):129. doi: 10.3390/pathogens8030129.
3
Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the L265P Gene Mutation.携带L265P基因突变的难治性IgA淋巴浆细胞淋巴瘤对依鲁替尼的反应
Mediterr J Hematol Infect Dis. 2019 Sep 1;11(1):e2019057. doi: 10.4084/MJHID.2019.057. eCollection 2019.
4
Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.支持诊断和决定治疗骨髓外华氏巨球蛋白血症的胸腔液 MYD88 L265P 突变：一例报告。
J Med Case Rep. 2020 Jul 13;14(1):98. doi: 10.1186/s13256-020-02404-x.
5
Reversible Systolic Heart Failure in a Patient on Ibrutinib Chemotherapy.接受依鲁替尼化疗的患者出现可逆性收缩性心力衰竭。
Cureus. 2022 Mar 17;14(3):e23266. doi: 10.7759/cureus.23266. eCollection 2022 Mar.
6
Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement.依鲁替尼治疗转化型淋巴浆细胞淋巴瘤伴中枢神经系统受累患者的疗效
Leuk Lymphoma. 2018 May;59(5):1256-1259. doi: 10.1080/10428194.2017.1369074. Epub 2017 Aug 29.
7
Cutaneous lymphoplasmacytic lymphoma with systemic metastasis in a cat.
J Vet Med Sci. 2011 Sep;73(9):1221-4. doi: 10.1292/jvms.10-0451. Epub 2011 May 6.
8
Waldenström macroglobulinemia: biology, genetics, and therapy.华氏巨球蛋白血症：生物学、遗传学与治疗
Blood Lymphat Cancer. 2016 Jul 26;6:49-58. doi: 10.2147/BLCTT.S84157. eCollection 2016.
9
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.伊布替尼治疗华氏巨球蛋白血症：最新证据与临床经验
Ther Adv Hematol. 2016 Aug;7(4):179-86. doi: 10.1177/2040620716654102. Epub 2016 Jun 13.
10
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.伊布替尼治疗复发或难治性 T 细胞淋巴瘤患者的初步试验。
Blood Adv. 2018 Apr 24;2(8):871-876. doi: 10.1182/bloodadvances.2017011916.

本文引用的文献

1
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.伊布替尼单药治疗复发/难治性转化弥漫大 B 细胞淋巴瘤。
Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):176-181. doi: 10.1016/j.clml.2020.11.023. Epub 2020 Dec 3.
2
Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.评估依鲁替尼治疗有症状的华氏巨球蛋白血症的疗效。
J Blood Med. 2019 Aug 27;10:291-300. doi: 10.2147/JBM.S183997. eCollection 2019.
3
Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement.
依鲁替尼治疗转化型淋巴浆细胞淋巴瘤伴中枢神经系统受累患者的疗效
Leuk Lymphoma. 2018 May;59(5):1256-1259. doi: 10.1080/10428194.2017.1369074. Epub 2017 Aug 29.
4
Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).转化型华氏巨球蛋白血症：临床表现与预后。法国创新白血病组织（FILO）对77例病例的多机构回顾性研究。
Br J Haematol. 2017 Nov;179(3):439-448. doi: 10.1111/bjh.14881. Epub 2017 Aug 2.
5
A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.新型布鲁顿酪氨酸激酶抑制剂依鲁替尼的综述
J Oncol Pharm Pract. 2016 Feb;22(1):92-104. doi: 10.1177/1078155214561281. Epub 2014 Nov 25.
6
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.依鲁替尼：首个布鲁顿酪氨酸激酶的共价抑制剂。
Future Oncol. 2014 May;10(6):957-67. doi: 10.2217/fon.14.51.
7
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.华氏巨球蛋白血症的基因组特征为高度重现的 MYD88 和 WHIM 样 CXCR4 突变，以及与 B 细胞淋巴瘤发生相关的小型体细胞缺失。
Blood. 2014 Mar 13;123(11):1637-46. doi: 10.1182/blood-2013-09-525808. Epub 2013 Dec 23.
8
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.瓦尔登斯特伦巨球蛋白血症中的 MYD88 L265P 体细胞突变。
N Engl J Med. 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710.
9
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.布鲁顿酪氨酸激酶是治疗慢性淋巴细胞白血病的一个很有前途的治疗靶点，它可以被 PCI-32765 有效靶向。
Blood. 2011 Jun 9;117(23):6287-96. doi: 10.1182/blood-2011-01-328484. Epub 2011 Mar 21.
10
Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Clinicopathologic features of 12 cases.发生于淋巴浆细胞淋巴瘤/华氏巨球蛋白血症患者的弥漫性大B细胞淋巴瘤。12例临床病理特征
Am J Clin Pathol. 2003 Aug;120(2):246-53. doi: 10.1309/R01V-XG46-MFCD-VNHL.